Orelabrutinib-Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Treatment of Marginal Zone Lymphoma: A Retrospective Study

被引：0
|
作者：
Li, He [1 ]
Liu, Jiazhuo [1 ]
Chen, Yuhui [1 ]
Tuohuti, Pazilaiti [1 ]
Wang, Yutong [1 ]
Tang, Xinzhu [1 ]
Xiang, Bing [1 ]
Jia, Yongqian [1 ]
Wu, Yu [1 ]
Tang, Yun [1 ]
Guo, Yong [1 ]
Wang, Jie [1 ]
Zheng, Yuhuan [1 ]
Liu, Yu [1 ]
Niu, Ting [1 ,2 ,3 ]
机构：
[1] Sichuan Univ, West China Hosp, Dept Hematol, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Facil Translat Med Sichuan, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, Collaborat Innovat Ctr Biotherapy, State Key Lab Biotherapy, Chengdu, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-206464
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6308 / 6309
页数：2
相关论文
共 50 条
  • [31] Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study
    Hess, Georg
    Dreyling, Martin
    Oberic, Lucie
    Gine, Eva
    Zinzani, Pier Luigi
    Linton, Kim
    Vilmar, Adam
    Jerkeman, Mats
    Chen, Jenny M. H.
    Ohler, Anke
    Stilgenbauer, Stephan
    Thieblemont, Catherine
    Lambert, Jonathan
    Zilioli, Vittorio Ruggero
    Sancho, Juan-Manuel
    Ubieto, Ana Jimenez
    Fischer, Luca
    Eyre, Toby A.
    Keeping, Sam
    Park, Julie E.
    Wu, James J.
    Siddiqi, Rubina
    Reitan, John
    Wade, Sally
    Salles, Gilles
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 749 - 759
  • [32] REAL-WORLD EXPERIENCE AMONG PATIENTS WITH MANTLE CELL LYMPHOMA AFTER COVALENT BRUTON TYROSINE KINASE INHIBITOR USE IN THE UNITED STATES: A RETROSPECTIVE ELECTRONIC HEALTH RECORD-DERIVED STUDY
    Hess, L.
    Khanal, M.
    Sugihara, T.
    Winfree, K.
    Konig, H.
    Abada, P. B.
    Goebel, B.
    Walgren, R. A.
    VALUE IN HEALTH, 2023, 26 (06) : S36 - S36
  • [33] Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium
    Devos, Timothy
    Verhoef, Gregor
    Steel, Eva
    Mazure, Dominiek
    Lewalle, Philippe
    Bron, Dominique
    Berneman, Zwi
    Benghiat, Fleur Samantha
    Mineur, Philippe
    Theunissen, Koen
    Zachee, Pierre
    Doyen, Chantal
    Put, Natalie
    Lejeune, Marie
    Van Eygen, Koen
    Havelange, Violaine
    Reusens, Michael
    Pluymers, Wim
    Peeters, Karen
    ACTA HAEMATOLOGICA, 2019, 142 (04) : 197 - 207
  • [34] Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Arakawa, Yoshiki
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Kitagawa, Junsaku
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY, 2021, 23 (01) : 122 - 133
  • [35] Phase Ib-II Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib, w/Lenalidomide and Rituximab in Relapsed / Refractory Mantle Cell Lymphoma
    Goy, Andre
    Feldman, Tatyana A.
    Leslie, Lori A.
    Panchal, Rima Panchal
    Nyirenda, Themba
    Skarbnik, Alan P.
    Yannotti, Kara
    Zenreich, Joshua
    Bejot, Colleen M.
    Stives, Susan
    Chow, Kar Fai
    Bhattacharyya, Pritish K.
    Yang, Xiao
    Richards, Ernest
    BLOOD, 2017, 130
  • [36] Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada
    Ball, Graeme
    Lemieux, Christopher
    Cameron, David
    Seftel, Matthew D.
    CURRENT ONCOLOGY, 2022, 29 (03) : 2021 - 2045
  • [37] Rapid clearance of HCV-related splenic marginal zone lymphoma under an interferon-free, NS3/NS4A inhibitor-based treatment. A case report
    Rossotti, Roberto
    Travi, Giovanna
    Pazzi, Annamaria
    Baiguera, Chiara
    Morra, Enrica
    Puoti, Massimo
    JOURNAL OF HEPATOLOGY, 2015, 62 (01) : 234 - 237
  • [38] Fixed-duration orelabrutinib plus bendamustine and rituximab versus continuous Bruton Tyrosine Kinase inhibitor (BTKi) in treatment-naive chronic/small lymphocytic leukemia (CLL/SLL): A multicenter, nonrandomized, pragmatic clinical trial
    Cao, L-L.
    Ding, K-Y.
    Song, H.
    Wang, C-C.
    Xu, Q.
    Zhou, C-Y.
    Hu, M-G.
    Ming, J.
    Wu, G-L.
    Fan, D-D.
    Feng, Y-Y.
    Wang, X-C.
    ANNALS OF ONCOLOGY, 2024, 35 : S612 - S612
  • [39] Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
    Lou, Yan
    Han, Xiaochun
    Kuglstatter, Andreas
    Kondru, Rama K.
    Sweeney, Zachary K.
    Soth, Michael
    McIntosh, Joel
    Litman, Renee
    Suh, Judy
    Kocer, Buelent
    Davis, Dana
    Park, Jaehyeon
    Frauchiger, Sandra
    Dewdney, Nolan
    Zecic, Hasim
    Taygerly, Joshua P.
    Sarma, Keshab
    Hong, Junbae
    Hill, Ronald J.
    Gabriel, Tobias
    Goldstein, David M.
    Owens, Timothy D.
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (01) : 512 - 516
  • [40] Treatment with Zanubrutinib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Previously Treated with Another Bruton Tyrosine Kinase Inhibitor in a US Community Oncology Setting
    Andorsky, David
    Wayne, Brittani
    Wentworth, Chuck
    Wang, Yunfei
    Goldfarb, Scott
    Yang, Keri
    Seymour, Erlene Kuizon
    Balk, Mark
    Maglinte, Gregory A.
    Zackon, Ira
    BLOOD, 2024, 144 : 7763 - 7764
12345